Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
Board Member/Acting CEO Provides Shareholder UpdateSale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation.Emphasis placed on advancing Elto Pharma, Inc....